Jazz Pharmaceuticals JAZZ
NASDAQ JAZZ
$212.86 -0.90 (-0.42%)
As of: Oct 21, 2026 · 1:48 PM EDT

Jazz Pharmaceuticals (JAZZ) Restructuring Costs (2011)

Updated

Jazz Pharmaceuticals (JAZZ) reported Restructuring Costs of $44 million for Q2 2018.

Analysis

Jazz Pharmaceuticals (JAZZ) Restructuring Costs (2011) Analysis & Trends

Over the twelve months ended Jun 30, 2018, Jazz Pharmaceuticals' Restructuring Costs came in at $57.7 million.

  • The Q2 2018 figure ranks as the highest quarterly Restructuring Costs in data going back to Q3 2011.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,134.13 Bn 1,102.72 Bn 19.71 Bn
2 Johnson & Johnson 616.20 Bn 534.73 Bn 17.26 Bn
3 AbbVie 501.09 Bn 474.20 Bn 12.70 Bn
4 Merck 367.41 Bn 321.79 Bn 12.21 Bn
5 Novartis Ag 297.88 Bn 261.87 Bn 11.24 Bn
6 Astrazeneca 261.36 Bn 235.05 Bn 12.86 Bn
7 Amgen 235.80 Bn 191.20 Bn 7.24 Bn
8 Gilead Sciences 190.78 Bn 164.97 Bn 6.22 Bn
9 Pfizer 169.43 Bn 116.08 Bn 10.94 Bn
10 Jazz Pharmaceuticals 13.46 Bn 7.28 Bn 1.09 Bn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2011 6.00 Mn
API Access

Jazz Pharmaceuticals Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=JAZZ&period=max&api_key=YOUR_API_KEY